98%
921
2 minutes
20
Background: Temporary mechanical circulatory support (tMCS) for cardiogenic shock (CS) is increasing despite knowledge gaps and variations in management practices. This document was created to provide clinicians with guidance regarding initiation, escalation, and de-escalation of tMCS in patients with CS.
Methods: An interdisciplinary, international expert panel using a structured literature appraisal and modified Delphi method derived consensus statements regarding triggers for prompt patient assessment and initiating tMCS in CS, assessing adequacy of support, readiness for tMCS weaning, and next steps in nonrecovery. Individual statements were graded on the basis of the quality of available evidence.
Results: The panel addressed 4 main questions aimed at initiation, escalation, and de-escalation of tMCS. On the basis of available literature review and expert consensus, 11 recommendations were formulated. Key principles included recognition of the need for patients with CS who have ongoing hemodynamic compromise, tissue hypoperfusion, and metabolic derangements to be considered for early tMCS initiation. An interdisciplinary shock team should be involved in management, with early referral when patient conditions require care beyond center capabilities. Discussions providing anticipatory guidance should be performed with patients and decision makers before initiating tMCS. Management of tMCS involves frequent, timely hemodynamic and tissue perfusion reassessments to determine the need for escalation or weaning. For patients unable to be weaned from tMCS, evaluation should include interdisciplinary assessment for advanced therapies, with palliation included as a consideration in care discussions.
Conclusions: A practical guide to initiation, escalation, and de-escalation of tMCS is provided. Center-specific approaches that are based on local capabilities should be implemented.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.athoracsur.2025.01.038 | DOI Listing |
Diagn Microbiol Infect Dis
September 2025
Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China. Electronic address:
Objectives: This study aimed to evaluate the prognostic value of metagenomic next-generation sequencing(mNGS) using Nanopore sequencing technology (NST) versus traditional culture methods in infectious disease cases.
Methods: We conducted a retrospective, single-center observational study comparing clinical outcomes between patients and specimen types in NST group and those in culture-based control group. Cox Proportional Hazards regression and Kaplan-Meier survival analysis were conducted to evaluate the association between diagnostic strategy and 28-day mortality.
Cancer Biol Med
September 2025
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
J Liq Biopsy
September 2025
Datar Cancer Genetics, Nashik, Maharashtra, India.
Liquid biopsy, specifically circulating tumor DNA (ctDNA) analysis, has emerged as a transformative tool in precision oncology, providing real-time, minimally invasive characterizations of the tumor and tumor dynamics. While tissue biopsy is a critical tool for baseline diagnosis of malignancy, it is often limited by sampling constraints and an inability to capture tumor heterogeneity. In this study, we explored the clinical utility of serial ctDNA testing in guiding therapeutic decisions across a cohort of 30 patients with diverse solid tumors.
View Article and Find Full Text PDFCurr Opin Pulm Med
September 2025
Departments of Medicine and Pediatrics, Medical University of South Carolina, Charleston, South Carolina, USA.
Purpose Of Review: The advent of CFTR modulators and the adoption of telemedicine during the COVID-19 pandemic have prompted reconsideration of cystic fibrosis (CF) care models. This review explores how care delivery may evolve in response to these changes.
Recent Findings: Emerging evidence highlights the heterogeneity in response to CFTR modulators, with some patients continuing to experience disease progression.